IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

OVERVIEW OF VARIOUS DISEASES ASSOCIATED WITH CARDIOVASCULAR SYSTEM

[1]Neha Jitendra Wajage, [2]Dr. Sunita Ogale, [3]Prof. Tanvi Pingale, [4]Saba Fatema Raheel Ahmed

[1]PG Student, [2]Principal, [3]Assitant Professor, [4]PG Student

[1]Department of Pharmacology,

[1]VIVA Institute of Pharmacy, Virar (E) Mumbai

Abstract: Blood is distributed throughout the body by the cardiovascular system, which is made up of the vascular network of blood arteries and the heart, which acts as the "pump". Red blood cells carry oxygen molecules attached to hemoglobin, which are then carried throughout the body to support cellular metabolism. Any obstruction of the blood supply resulting from plaque accumulation in the endothelium layer would cause a stoppage in blood flow and consequently oxygen deprivation (ischemia). This is referred to as an infarct and would cause necrosis of the damaged vessel's distal region. This article explains the normal structure and physiology of the cardiovascular system, as well as several common illnesses related with it. It also includes a brief management guide for myocardial infarction, a frequent heart condition, Angina, Atherosclerosis, Congestive Heart Failure (CHF); etc. A thorough grasp of the cardiovascular system and the diseases that are linked to it will help the patient to deeply understand the disease and take precautions related it.

Keywords - Cardiovascular system, Blood, Disease, Angina, Myocardial infraction, CHF

I. INTRODUCTION

As the name suggests the heart (cardio) and blood vessels (vascular) make up the cardiovascular system. Blood is constantly and continuously pumped by the heart, while the blood arteries form the extensive network that allows blood to be carried throughout the body. The circulatory system's primary duties include pumping blood to and from the body's tissues, organs, and systems as well as eliminating metabolic waste products. The blood carries nutrients, oxygen, carbon dioxide, metabolic waste products, water, electrolytes, hormones, and other blood products to the intended organs. It is noteworthy that the cardiovascular system is strongly associated with the lymphatic system, which improves the functionality of the latter. Only when enough pressure is applied to the blood arteries by the heart's beating motion can blood flow across the vast vascular network. [1]

Location of the Heart:

The diaphragm supports the heart, which is situated close to the mediastinum, or middle of the thoracic cavity [2].The double-walled outer fibrous membrane that surrounds the heart is called the pericardium, and it serves to protect the organ, anchor it to the surrounding organs, and keep it from overstretching or overflowing with blood during systole [3]. The inner layer of the pericardium, a serous membrane, is known as the visceral pericardium or epicardium, while the outside layer, a fibrous sac, is called the parietal pericardium [4]. The heart is thought to be around the size of the owner's closed fist, measuring around 12 cm in length and 9 cm in width [5]. The weight of the heart is almost between 250 to 390 g in men and 200 to 275 g in women.

Structure of Heart:

The pericardium, myocardium, and endocardium are the three layers that make up the heart wall. The double-walled outer fibrous membrane that surrounds the heart is called the pericardium, and its functions include protecting the organ, securing it to the surrounding organs, and preventing the heart from overstretching or filling with blood during systole. The inner layer of the pericardium, a serous membrane, is known as the visceral pericardium or epicardium, while the outside layer, a fibrous sac, is called the parietal pericardium. The two layers are separated by a thin layer of serous fluid, known as the pericardial cavity, which holds between 10 and 30 milliliters of pericardial fluid. This liquid makes it possible for the heart to beat without resistance. The thickest and central layer of the heart wall is called the myocardium. Because of how easily blood can be expelled from the heart chambers because to its muscular contractions, it is also known as the cardiac muscle. The heart's innermost layer is called the endocardium. It is made up of connective tissue and thin, smooth endothelium, which permit blood to flow freely. Antithrombotic factors are released by the endothelium layer and prevent blood clots from sticking to the endocardium. [1]

The Chambers of the Heart:

The right atrium, left atrium, right ventricle, and left ventricle are the four chambers that make up the heart, which is separated into the right and left sides [5]. The septum is the wall that divides the left and right halves of the heart. The purpose of this septum is to keep the oxygen-poor blood from the right side of the heart from combining with the oxygen-rich blood from the left side of the heart [6]. The terms "right atrium" and "left atrium" (plural: "atria") refer to the two upper chambers, whereas "right and left ventricles" refer to the two bottom chambers [7]. It is significant to remember that the ventricles are larger and thicker than the atria. With their larger myocardial layer, the ventricles make up a large portion of the heart's mass. The amount of resistance that must be overcome before blood can be ejected from the chambers is directly correlated with the thickness of each chamber [8]. Because of the tremendous resistance that must be overcome before blood can be ejected into the pulmonary and systemic capillaries, the ventricular walls are therefore thicker.

Fibrous Skeleton of the Heart:

There are four dense fibrous rings known as annuli fibrosi cordis that form anchorage for the firm attachments of the atria and the ventricles tissues as well as the valvular tissues [9].

Valves of the Heart:

The heart's valves guarantee that blood only flows through its chambers in one direction [4]. Atrio-ventricular valves stop blood from flowing backward from the ventricle into the atria. Because it has three cusps, the heart's right valve is known as the tricuspid valve, while the heart's left valve is known as the bicuspid or mitral valve because it has two cusps [2].Similar to the functions of the atrioventricular valves, there are valves in the aorta and the pulmonary artery. We refer to these as semilunar valves [3].

Blood Flow through the Heart:

The vessels that carry blood to and from the heart are mostly of three sorts. These comprise the capillaries, veins, and arteries. Blood is transported to and from the heart by the veins and arteries, respectively. One way to think about blood vessels is as a closed delivery system that starts in the heart and ends there [10].The heart is supplied and emptied by multiple major arteries carrying blood. The tricuspid valve allows the right atrium to be emptied of deoxygenated blood from the systemic circulation, which is then returned to the heart via the superior and inferior venae cavae [5]. After entering the pulmonary arteries, the blood is subsequently pumped from the right ventricle into the left and right lungs to receive oxygen. The lungs' capillary-alveolus interphase is where gas exchange takes place, causing carbon dioxide to be expelled and oxygen to be absorbed [11]. The four sets of pulmonary veins carry the oxygenated blood from the lungs to the left atrium, where the biscupid (mitral) valve pumps the blood into the left ventricle. Through the semilunar valves, oxygenated blood from the left ventricle is expelled into the aorta, where it then flows to the body's systemic veins [6]. The term "pulmonary circulation" refers to the flow of blood from the right ventricle to the lungs and from the lungs to the left atrium [3]. The blood that travels from the left ventricle to the body's systemic vessels via the aorta and then returns to the right atrium through the superior and inferior venae cavae is known as the systemic circulation [12]. It is significant to remember that the coronary veins return the deoxygenated blood from the heart tissues to the right atrium, whilst the coronary arteries provide the heart tissues with oxygenated blood [4]. The heart pumps blood by a mechanism that involves the contraction and relaxation of the myocardial layer. The cardiac cycle is the contraction and

subsequent relaxation of the ventricle's myocardial layer [9]. Blood from the atria fills the ventricles during diastole, when they relax, and is expelled into the circulation during systole, when they contract.

The Conduction System of the Heart:

Electrical impulses pass through the myocardium of the four chambers of the heart to enable the cardiac cycle to remain consistent. The electrical impulses are activated by this, which is referred to as the cardiac action potential. The heart's conducting system consists of the following: the right and left bundle branches, the Purkinje fibers, the His bundle, the atrioventricular (AV) node, and the sinoatrial (SA) node [6]. The SA node, which is located in the right atrium close to the superior vena cava entrance, is where the electrical impulses begin. Because its impulses are initiated far faster than those of the other neuromuscular cells, it is frequently referred to as the heart's natural pacemaker [4]. Atrial contraction is brought on by the impulses of the SA node. Electrical impulses pass on from the SA node to the AV node via the posterior internodal pathway, which connects both left and right atria as well as the SA node and the AV node [13]. Because of its location at the bottom of the right atrium, the AV node is able to mediate conduction between the ventricles and the atria. Because of its special placement inside the atria, it is activated last in the atria, giving blood adequate time to empty into the ventricle prior to ventricular contraction, preventing backflow [4]. The conducting fibers of the AV node unite to form the bundle of His (AV bundle) on the posterior edge of the interventricular septum. The left bundle branch and the right bundle branch are formed by the division of the bundle of His. The apex of the left ventricle is reached by the left bundle branch (LBB), and the right ventricular apex is reached by the right bundle branch (RBB). The Purkinje fibers are the terminal branches of the left bundle branch and the right bundle branch. They encourage quick impulse dispersion throughout the apices and extend to the ventricular apexes. The heart's pumping motion is rhythmic in nature and may contract and relax on its own without the help of the nerve supply; nevertheless, the heart's nerve supply, which comes from the medulla oblongata, affects the rate of contraction [11].

II. DIFFERENT TYPES OF HEART DISEASE

The heart and its blood arteries make up the cardiovascular system. The heart's structure, the arteries, and anomalies in the conduction system are all affected by the many illnesses of the cardiovascular system. These comprise angina, cardiogenic shock, rheumatic heart disease, cardiomyopathy, atherosclerosis, myocardial infarction, endocarditis, and heart failure/congestive heart failure. Since coronary heart disease (CHD) affects both men and women equally and has a significant financial impact, it has been considered the most significant cardiac condition [7].

It is also known as coronary artery disease (CAD) or ischemic heart disease (IHD). One of the most common cardiovascular illnesses affecting people worldwide is CAD, which has been the main cause of death in both developing and industrialized nations [12]. The American Heart Association classifies heart failure, dysrhythmia, sudden cardiac arrest, myocardial infarction, and angina pectoris under the general category of CAD, which accounts for one in six fatalities in the United States[7]. The main cause of heart disease has been identified as CAD, which results from atherosclerosis [14]. Peripheral arterial disease (PAD), an atherosclerotic disease of the arteries supplying the limbs that can lead to claudication, is a related illness of the cardiovascular system. Following is the detailed Information related this cardiovascular disease

Various Heart Diseases is as follow:

1. Angina
2. Cardiogenic Shock
3. Atherosclerosis
4. Myocardial Infarction
5. Congestive Heart Failure

1. ANGINA

The most typical sign of ischemic heart disease, which is a leading cause of morbidity and death globally, is angina, or chest discomfort. A complete history and physical examination are essential in distinguishing between cardiac and non-cardiac causes of chest discomfort and in identifying patients who are suffering from acute coronary syndrome. One of the symptoms of acute coronary syndrome (ACS) is angina, which can be further classified as unstable or stable. The definition of stable angina is when symptoms appear solely during physical effort. Evaluation and treatment of unstable angina or symptoms that arise when at rest must happen more quickly. Angina symptoms affect about 9 million patients in the US, and treating these patients effectively depends on identifying their symptoms. [15]

Pathophysiology:
The heart needs a sufficient quantity of oxygen to produce energy and maintain contractility. Ischemia increases the rate of anaerobic glycolysis within cells. This raises the venous return of the damaged or ischemic myocardium's levels of lactate, potassium, and hydrogen. The affected area experiences hypokinesia or akinesia due to hydrogen ions competing with calcium ions. Exercise, stress, and low body temperature are triggers that would result in a metabolic mismatch and lead to stable angina. [15].

Differential Diagnosis:
The body systems that can be included in the differential diagnosis of angina are:

a) Digestive: peptic ulcer illness, hiatal hernia, and gastroesophageal reflux
b) Pulmonary: pulmonary embolism, pneumonia, and pneumothorax
c) Musculoskeletal: damage to the chest wall, muscle spasms, rib fractures, and osteochondritis
d) Mental health: panic episodes, overall anxiety
e) Nonischemic heart conditions: myocarditis and pericarditis
f) Vascular: aortic dissection

Signs and Symptoms of Angina:

a) Fatigue.
b) Aching
c) Dizziness.
d) Upset stomach or vomiting
e) Feeling of heaviness or pressure.
f) Burning.
g) Feeling of fullness in your chest.
h) Discomfort.

Treatment and Management:
The goal of treating chronic stable angina is to both control the symptoms and delay the onset of cardiac events. Multifaceted management includes crucial treatment components such as medical therapy, risk factor control, and lifestyle adjustments [16]. Revascularization may be tried in situations where symptoms are not improving with medication; however, while it may be effective in managing symptoms, there is no proof that it will lower significant cardiovascular events in comparison to medication [17].
Regular exercise, maintaining a healthy weight, and quitting smoking are examples of lifestyle improvements that should be promoted. Reducing blood pressure, cholesterol, and blood sugar are examples of risk factor adjustment. A number of medications, such as aspirin, statins, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, are used to modify risk factors and stop disease progression [16].
In addition to assisting in symptom management, medical therapy can help reduce the chance of atherosclerosis progression and cardiac events [16].
Antianginal drugs can be categorized according to how they reduce angina symptoms. Generally speaking, myocardial oxygen consumption is reduced to achieve symptomatic management.
Since heart rate is the primary determinant of oxygen consumption, an increase in heart rate is the primary cause of most anginal episodes [15]. Three kinds of medications which are ivabradine, non-dihydropyridine calcium channel blockers, and beta-blockers, reduce angina symptoms by slowing the heart rate. Patients with reduced ejection fraction and left ventricular dysfunction should not take calcium channel blockers.

Vascular smooth muscle relaxation is another treatment method for anginal symptoms. This causes the coronary arteries to dilate, which improves the capacity for perfusion. Nicorandil, nitrates, and dihydropyridine calcium channel blockers are the medications that affect this mechanism [15].
Ranolazine, which inhibits the late sodium current in ventricular myocardial cells, is another medication used for chronic stable angina. This helps to decrease diastolic contractile dysfunction [18].
Reducing discomfort, preventing myocardial damage, and lowering morbidity and death are the goals of treatment for unstable angina

a) Nitrates: Nitrates are used to relieve chest pain but have little effect on mortality. They produce vasodilation, which lowers the end-diastolic volume and preload of the left ventricle. As a result, the heart uses less oxygen. If you have hypotension or have taken phosphodiesterase inhibitors within the last 48 hours, they should not be taken together.
b) Morphine: When nitrates are unable to provide enough pain relief, morphine,which has no mortality benefit—is utilized. In addition to analgesia, it also induces mild vasodilation.
c) Beta-blockers: they lower death rates. They lower blood pressure, heart rate, and contractility, which lower the oxygen demand on the heart.
d) Antiplatelet medications: in patients with acute coronary syndromes, the risk of cardiovascular events, such as acute myocardial infarction, stroke, and cardiovascular death, is reduced by dual therapy with aspirin and either clopidogrel, ticagrelor, or prasugrel.
e) Anticoagulants: when used with antiplatelet medicines, they lower the risk of re-infarction and thereby decrease mortality. It is administered intravenously as a quick fix.

2. CARDIOGENIC SHOCK

A main cardiac condition known as cardiogenic shock is characterized by tissue hypoperfusion as demonstrated by both clinical and biochemical indicators. Clinical criteria include urine output of less than or equal to 30 mL/hr., cool extremities, and a systolic blood pressure of less than or equal to 90 mm Hg for more than or equal to 30 minutes or support to maintain systolic blood pressure less than or equal to 90 mm Hg. A low cardiac index (less than or equal to 2.2 liters per minute per square meter of body surface area) and an elevated pulmonary-capillary wedge pressure (more than 15 mm Hg) are two examples of hemodynamic criteria.
A low cardiac output state of circulatory failure resulting in end-organ hypoperfusion and tissue hypoxia is known as cardiogenic shock. Although several conditions impairing the myocardium, valves, conduction system, or pericardium can potentially induce cardiogenic shock, acute myocardial infarction is the most frequent cause of the condition. Patients with cardiogenic shock continue to have significant rates of morbidity and mortality despite advancements in mechanical circulatory support and reperfusion therapy [19]

Pathophysiology:
Cardiogenic shock is a complicated and poorly known etiology. Systolic and diastolic left ventricular function is disrupted by myocardial ischemia, which results in a significant reduction in myocardial contractility. This then triggers a vicious cycle that could be disastrous, resulting in low blood pressure and decreased cardiac output, which prolongs coronary ischemia and contractility impairment. Numerous physiological compensating mechanisms follow. Among them are:

- Peripheral vasoconstriction brought on by sympathetic nervous system activation may enhance coronary perfusion at the expense of higher afterload, and
- Myocardial ischemia is made worse by tachycardia, which raises the oxygen demand on the heart.

Pathologic vasodilation, which results from the release of strong systemic inflammatory indicators including interleukin-1, tumor necrosis factor-a, and interleukin-6, subsequently offsets these compensatory mechanisms. Higher concentrations of peroxynitrite and nitric oxide are also generated; these substances are known to be cardiotoxic and to contribute to pathologic vasodilation. This self-perpetuating loop eventually results in multiorgan failure and death because it fails to properly meet the metabolic demands of the tissues and causes global hypoperfusion. Appropriate treatment approaches are needed to break this cycle [20].

Signs and symptoms:

1) Severe shortness of breath.
2) Rapid breathing.
3) Sudden, rapid heartbeat (tachycardia)
4) Loss of consciousness.
5) Weak pulse.
6) Low blood pressure (hypotension)
7) Sweating.
8) Pale skin

Treatment:

Cardiogenic shock is an emergency that needs to be treated with resuscitation medicine right once to prevent irreparable organ damage. Patients with cardiogenic shock have a very poor prognosis if the underlying cause is reversed and medication therapy is started as soon as possible to maintain blood pressure and respiratory assistance [21].

For individuals experiencing cardiogenic shock as a result of myocardial infarction, early restoration of coronary blood is the most crucial intervention and the recommended course of treatment.

Medical Management

- Rapidly preventing irreparable end-organ damage and restoring cardiac output are the two main objectives of medical therapy.
- Uncertainty surrounds the best vasoactive agent to use in cardiogenic shock. When a patient has severe hypotension (systolic blood pressure less than 70 mm Hg) or hypotension that is not improving with other drugs, norepinephrine is recommended above dopamine because the latter has been linked to an increased risk of arrhythmias and mortality in this patient population. However, in individuals who have recently experienced a myocardial infarction, norepinephrine should be taken cautiously as it may produce tachycardia and raise the myocardial oxygen demand.
- Dobutamine is a commonly used medication that possesses beta-1 and beta-2 agonist qualities that can enhance cardiac contractility, decrease end-diastolic pressure in the left ventricle, and raise cardiac output.
- Another popular inotrope that has been demonstrated to lower left ventricular filling pressures is milrinone.
- Patients without symptoms of fluid overload should take more than 200 milliliters of saline or lactated ringer solution every 15 to 30 minutes.
- If there are no contraindications, individuals who are not good candidates for coronary artery bypass grafting or percutaneous coronary intervention should get fibrinolytic therapy.
- Heparin and aspirin are prescribed to patients suffering from acute coronary syndrome or myocardial infarction. It has been demonstrated that they are useful in lowering mortality.

3. ATHEROSCLEROSIS

Hyperlipidemia and lipid oxidation lead to atherosclerosis, which has long been a leading cause of death in affluent nations. It is a vascular intima disease that can affect any part of the vascular system, including the aorta and coronary arteries. It is characterized by intimal plaques [22].

The Greek word "atherosclerosis" refers to the build-up of fat and thickening of the artery's intimal layer. The fibrous cap covers the fatty substance in the plaque's central core. The terms "atherosclerosis" and "sclerosis" refer to the build-up of fat and many macrophages as well as the fibrosis layer that includes connective tissue, leukocytes, and smooth muscle cells (SMC) [23]. These days, atherosclerosis is a frequent illness where the inner layers of arteries develop fatty deposits known as atheromatous plaques. Little cholesterol crystals that are deposited in the intima and the smooth muscle beneath it are the first step in the formation of these plaques. Subsequently, as the fibrous tissues and surrounding smooth muscle proliferate, the plaques develop and protrude inside the arteries, reducing blood flow. Sclerosis, or hardening of the arteries, is brought on by fibroblasts' creation of connective tissue and calcium deposits in the lesion. Lastly, thrombosis and clot development brought on by the arteries' uneven surface cause an abrupt blockage of blood flow [24].

Increased oxidative damage has been linked to hyperlipidemia and hyperglycemia, which impacts lipoprotein levels and antioxidant status. In addition to their antioxidant properties, studies have demonstrated that cholesterol-lowering medicinal herbs can lower blood lipid levels, particularly after meals. Consequently, they can stop the damage to the vascular endothelium and atherosclerosis [25].

Signs and symptoms:

The arteries that are impacted and the degree of blood flow obstruction determine the symptoms. The symptoms of coronary heart disease include angina (chest pain), cold sweats, dizziness, excessive fatigue, palpitations (heart palpitations), shortness of breath, nausea, and weakness.

4. MYOCARDIAL INFARCTION

The phrase "myocardial infarction" (MI) refers to a harmful cardiovascular event that results from blood clots or plaques forming in the coronary artery intima, which restricts blood flow to the heart and damages the myocardium by depriving it of oxygen[26].

MI is seen as a medical emergency that needs to be treated quickly by healthcare professionals in order to improve patient outcomes [27].Individuals who have a medical history of atherosclerosis, transient ischemic attacks (TIAs), smoking, excessive alcohol consumption (which raises LDL cholesterol levels), use of recreational drugs like cocaine, diabetes, and obesity are among the risk factors for MI [28].

Pathophysiology:

MI is brought on by a blood clot or atheromatous plaque that obstructs the coronary artery's intima. Due to oxygen deprivation, this decreases or obstructs blood flow to the cardiac muscle tissues distal to the afflicted artery, which causes cell death (necrosis) [13]. An infarct is a type of injury caused by oxygen starvation. The location of the obstruction, the size of the afflicted tissue area, and the length of the occlusion all determine how much of it is blocked. Occasionally, there is also damage to the endocardium and pericardium [14].

A collagen scar accumulates in the heart tissue after an infarct occurs in the myocardium, which makes it difficult for the damaged portion of the heart to contract effectively. It also has an impact on cardiac conductivity, which impedes the heart's ability to pump blood effectively and, as a result, reduces tissue perfusion.

Investigations:

Medical tests such as an electrocardiogram (ECG), angiography, echocardiography, chest X-ray, and blood chemistry, including cardiac enzymes, urea and electrolytes, complete blood count, and serum biomarkers like troponin, can be used to identify MI. Depending on the changes shown on the ECG, MIs are classified into two types: non-ST segment elevation myocardial infarction (NSTEMI), which is primarily caused by partial or intermittent occlusion of the artery, and ST-segment elevation myocardial infarction (STEMI), which is typically caused by complete and persistent occlusion of the artery[27].

Symptoms of MI:

MI symptoms include following:

1. chest pain,
2. radiating from left arm to neck,
3. tightness in the chest,
4. anxiety,
5. shortness of breath (dyspnea),
6. cyanosis,
7. excessive sweating (diaphoresis),
8. nausea,
9. hypotension,
10. vomiting, irregular pulse,
11. fatigue, weakness, stress,
12. depression,

13. signs of shock,
14. loss of consciousness
15. death [26]

Research appears to indicate that women frequently exhibit symptoms that are different from those of men. Men are more likely to experience pain in the center of their chest, while women are more likely to experience discomfort in the jaw, upper back, neck, and arm. [29].

Treatment of MI:

Taking a resting electrocardiogram and starting antithrombotic medication are the first steps in treating MI. The course of treatment may vary according on the kind of MI, STEMI or NSTEMI. Aspirin should be started at a 300 mg loading dose for STEMI very away, according to the National Institute for Health and Care Excellence (NICE) (2020), and should be continued until otherwise directed. Patients with cyanosis, dyspnea, or hypoxemia (oxygen saturation of less than 90%) should prioritize getting oxygen supplements [27]. Depending on eligibility, reperfusion therapy—percutaneous coronary intervention (PCI) or fibrinolysis—is also strongly advised; if not, medical management will be provided.

In addition, where contraindicated, first antiplatelet therapy for NSTEMI is a continuous 300 mg loading dose or prompt angiography. If the creatinine level is more than 265 micromoles/litre , unfractionated heparin with a dose tailored to the clotting function may also be taken into account.

Chest pain needs to be treated with glyceryl trinitrate, also known as nitroglycerin. To reduce pain, opioid analgesics like pethidine or morphine can also be used. Antihypertensive medications, such as beta-blockers, ACE inhibitors, or calcium channel blockers, can also be used to lower blood pressure and increase the heart's oxygen demand. However, according to NICE (2020) guidance, calcium channel blockers should no longer be routinely prescribed as secondary prevention following myocardial infarction.

5. CONGESTIVE HEART FAILURE

The intricate clinical illness known as congestive heart failure (CHF) is marked by an inefficient heartbeat, which compromises the body's blood flow. Any condition affecting blood ejection from the ventricles into the systemic circulation or ventricular filling might lead to CHF. Patients typically arrive with decreased exercise tolerance, dyspnea and exhaustion, and pulmonary or systemic congestion. The causes of heart failure are numerous and diverse. When assessing a patient with HF, a thorough evaluation is necessary. Regardless of the underlying etiology, the overall therapy strives to stabilize hemodynamic state and relieve systemic and pulmonary congestion. In addition to reviewing the diagnosis, treatment, and follow-up of congestive heart failure, this exercise emphasizes the importance of the healthcare team in enhancing patient outcomes.

The American College of Cardiology (ACC) and the American Heart Association (AHA) define congestive heart failure (CHF) as "a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood." Ischemic heart disease is the world's leading cause of death and the primary cause of CHF, which is a common disorder with a high rate of morbidity and mortality. With an estimated 26 million people living with CHF, it raises healthcare costs, lowers functional capacity, and has a substantial negative impact on quality of life. It is crucial to diagnose and treat the condition in order to avoid repeat hospitalizations, lower morbidity and mortality, and improve patient outcomes [30].

Heart failure's (HF) etiology is broad and diverse. Regardless of the underlying etiology, the overall therapy strives to stabilize hemodynamic state and relieve systemic and pulmonary congestion. A comprehensive strategy including patient education, optimal medication delivery, and reducing acute exacerbations is needed to manage heart failure (HF).

Heart failure is categorized using left ventricle ejection fraction (LV EF).

- HFrEF (heavy-duty ejection fraction): LV EF < 40%
- LV EF 41%–49% with signs of HF (high cardiac biomarkers or elevated filling pressures) and moderately reduced ejection fraction (HF).
- LV EF ≥ 50% with indications of HF (higher filling pressures or cardiac biomarkers) are associated with HF with preserved ejection fraction, or HFpEF.

- HF with an enhanced ejection fraction: LV EF >40%, compared to LV EF previously reported as being ≤ 40%

Although historically underdiagnosed, patients with HFpEF account for 44% to 72% of CHF cases. LV EF ≥ 50% on an echocardiography (echo) shows signs of compromised diastolic function. The primary risk factor is hypertension (HTN), with additional risk factors including female sex, diabetes, and advanced age [31]. Together, the ACC and AHA use a two-stage classification system for heart failure (HF), with the first two stages being asymptomatic and the second two based on the severity of symptoms.
ACC/AHA Heart Failure Stages:

- Stage A: HF risk is present. There are risk factors but no symptoms, structural heart disease, or indications of increased cardiac biomarkers. Having a genetic variation for cardiomyopathy, diabetes, metabolic syndrome, hypertension, and cardiotoxic medicines are risk factors.
- Pre-HF is Stage B. Even though a patient does not exhibit any symptoms of heart failure, they may nevertheless have structural heart disease, consistently raised cardiomarkers in the absence of other causes such as myocarditis or chronic renal disease, or evidence of elevated filling pressures (via invasive or noninvasive examination).
- Patients in Stage C have structural heart disease and have experienced HF symptoms in the past or present.
- Stage D: Patients who, despite focused medical therapy guided by guidelines, continue to have refractory symptoms that interfere with daily functioning or require repeated hospitalization.

Sign and symptoms:

a) Shortness of breath with activity or when lying down.
b) Fatigue and weakness.
c) Swelling in the legs, ankles and feet.
d) Rapid or irregular heartbeat.
e) Reduced ability to exercise.
f) Wheezing.
g) A cough that doesn't go away or a cough that brings up white or pink mucus with spots of blood.
h) Swelling of the belly area

Treatment:

Reducing hospitalizations, increasing cardiac mortality, and improving symptoms and quality of life are the objectives of treatment for chronic CHF. Pharmacologic therapy aims to manage symptoms and start and increase medications that lower mortality and morbidity in heart failure [30].

For Stage A (At-Risk for HF)

- Guideline-directed medical therapy (GDMT) is recommended for the treatment of hypertension in individuals.
- SGLT-2 inhibitors are recommended in people with type 2 diabetes to lower hospitalization rates for heart failure.
- It is recommended to make lifestyle changes such eating a balanced diet, getting regular exercise, keeping a normal weight, and quitting smoking.
- When a patient has been diagnosed with coronary artery disease, their cardiovascular conditions should be optimally managed.
- Multidisciplinary care should be provided to patients who are at risk for heart failure (HF) as a result of being exposed to cardiotoxic drugs, such as chemotherapy.
- Screening for natriuretic peptides and routine assessment are advised.

For Stage B (Pre-HF)

- ACEi should be taken to reduce mortality and prevent clinical HF in individuals with left ventricular EF of less than 40%.
- The usage of a statin plus beta-blocker is advised for patients with LV EF ≤ 40% and signs of acute coronary syndrome or myocardial infarction, in order to reduce adverse cardiovascular events, mortality, and CHF.

- A primary prevention ICD is advised for patients with LV EF ≤ 30%, appropriate medical therapy, NYHA-class I, and an anticipated meaningful survival of more than a year.
- In order to prevent HF symptoms, individuals with LV EF ≤ 40% are advised to take beta-blockers, regardless of the cause.
- It is best to avoid using thiazolidinediones and non-dihydropyridine calcium channel blockers in patients with LV EF ≤ 50% as they increase the risk of unfavorable outcomes and heart failure hospitalizations.
- There are guidelines for treating asymptomatic valvular heart disease with relation to valve replacement, repair, or interventions.
- Guidelines specific to patients with congenital cardiac disease also exist.

For Stage C (HF)

- For HF patients, multidisciplinary management is recommended to improve self-care and mortality.
- For the best possible care, social support and patient education are necessary.
- Vaccination against respiratory diseases lowers mortality rates.
- During healthcare interactions, it is sense to screen patients for depression, low literacy, limited social support, frailty, and resource and travel constraints.
- A diet low in salt is advised.
- Exercise training is a useful tool for raising living standards and functional class.
- Diuretics lessen the progression of heart failure and relieve symptoms in people with congestion.
- Patients who do not respond well to a moderate or high dose of loop diuretics should be the only ones to receive a thiazide diuretic, such as metolazone.
- Digoxin has a limited impact in lowering the all-cause hospitalization rate, although it may be taken into consideration in symptomatic patients with sinus rhythm who are not responding to sufficient goal-directed therapy.
- An ARNi is advised for individuals with HFrEF in order to lower mortality and morbidity. Patients who are intolerant of ACEi should not be given ARNi; instead, an ARB should be administered. When a patient's finances prevent them from taking an ARNi, using an ACEi or ARB is advised. It is not recommended to utilize ARNi for 36 hours after the last ACEi dose. It is highly advised, and has a great economic benefit, to switch to ARNi for patients who are tolerating ACEi/ARB well. Similar to ACEi, patients with a history of angioedema shouldn't be administered ARNi.
- The beta-blockers carvedilol, bisoprolol, or sustained-release metoprolol are useful in lowering hospitalization and death rates for individuals with HFrEF.
- Regardless of diabetic status, SGLT-2 inhibitor usage is advised for individuals with HFrEF to lower hospitalization rates and mortality from heart failure.
- In order to lower morbidity and mortality, it is advised that African American patients with HFrEF and NYHA class III–IV who are already getting optimal medical therapy (OMT) add hydralazine and nitrate. This has significant economic worth.
- A hydralazine and nitrate combination may be useful for patients with HFrEF who are intolerant to RAASi or for whom RAASi is not recommended because of renal impairment.

For Stage D (Advanced HF)

- It is recommended to refer to an HF specialist.
- It seems sense to administer device therapy and inotropic support to patients who are waiting for a heart transplant or mechanical cardiac support. Patients who are not suitable for a transplant or mechanical cardiac support can use inotropic support alone.
- As a stopgap before a transplant, mechanical cardiac support such as an ECMO or a durable left ventricle assist device (LVAD) can be helpful.
- A heart transplant is recommended to increase survival and quality of life for very selected people.
- Care goals ought to be determined through collaborative decision-making. This involves taking frailty, concomitant conditions, and socioeconomic support into account. After a collaborative decision-making process, palliative care should be provided as needed.[32]

III. CONCLUSION

Many regions of the world are currently at moderate or high risk of cardiovascular disease (CVD), and as behavioral, biological, and social risks accumulate, so will the effect of chronic diseases globally in the future. For many years to come, CVDs, primarily ischemic heart disease (IHD) and stroke will continue to be the leading cause of death worldwide. Early childhood prevention is essential, as is ongoing prevention throughout the life course. It is necessary to place a fresh and considerably higher focus on early childhood development, with programs for mother and child health paying more attention to the risk of chronic diseases. However, even if childhood prevention is quickly put into practice, trends in main risks will impact incidence for several decades to come. Thus, to lower the death rate in middle age and older adulthood, coordinated and combined primary and secondary preventive activities are also required. The structure and operation of the heart, as well as common heart problems and various heart related disease have all been covered in this article. A thorough understanding of the typical anatomy and physiology of the cardiovascular system can helps to understand the heart and the detailed information related heart disease. Early detection and care of patients who are deteriorating can lead to better patient outcomes.

IV. ACKNOWLEDGMENT

I would like to express my profound gratitude to Mrs. Sunita Ogale (Principal) from Pharmacology Department and Mrs. Tanvi Pingale (Professor) of VIVA Institute of Pharmacy, Virar, Mumbai University for their guidance and support for my review work titled “OVERVIEW OF VARIOUS DISEASES ASSOCIATED WITH CARDIOVASCULAR SYSTEM”

V. REFERENCES

1. Wuche C. 2022 Sep 22. The cardiovascular system and associated disorders. Br J Nurs, 31(17):886-892. doi: 10.12968/bjon.2022.31.17.886. PMID: 36149425.
2. Cook N, Shepherd A, Boore J. 2021. Essentials of anatomy and physiology for nursing practice. 2nd edn. London: Sage Publications: Chapter 12
3. Marieb E, Keller S. 2018. Essentials of human anatomy and physiology. 12th edn. Harlow: Pearson Education;
4. Peate I, Nair M. 2015. Anatomy and physiology for nurses at a glance. Oxford: Wiley Blackwell.
5. Nair M. 2018. The heart and associated disorders. In Peate I (ed). Fundamentals of applied pathophysiology: an essential guide for nursing and healthcare students. 3rd edn. Hoboken NJ: John Wiley & Sons.
6. Tortora G, Derrickson B. 2017. Tortora's principles of anatomy & physiology. 15th edn. Singapore: John Wiley & Sons: Chapter 20
7. Banasik JL. 2019. Alterations in cardiac function. Chapter 18 in Banasik JLCopstead LC (eds). Pathophysiology. 6th edn. St Louis: Elsevier.
8. Hubert RJ, VanMeter KC. 2018. Gould's pathophysiology for the health professions. 6th edn. St Louis: Elsevier: chapter 12
9. McCance K. 2019. Structure and function of the cardiovascular and lymphatic systems. In: Huether SMcCance KBrashers V (eds). Understanding pathophysiology. 7th edn. St Louis: Elsevier;
10. Martini F, Nath J, Bartholomew E. 2014. Fundamentals of anatomy and physiology. 10th edn. Harlow: Pearson Education
11. Waugh A, Grant A. 2018. Ross and Wilson anatomy and physiology in health and illness. 13th edn. Oxford: Elsevier;
12. Marieb E, Hoehn K. 2018. Human anatomy and physiology: global edition. 11th edn. Harlow: Pearson Education.
13. Edwards S. 2014. The cardiovascular system. Chapter 8 in Richard AEdward, S (eds). Essential Pathophysiology for Nursing and Healthcare Students. Berkshire: Open University Press.
14. Brashers VL. 2019. Alterations of cardiovascular function. Chapter 26 in Huether SMcCance KBrashers V (eds). Understanding pathophysiology. 7th edn. St Louis: Elsevier

15. Balla C, Pavasini R, Ferrari R. 2018. Treatment of Angina: Where Are We? Cardiology. 140(1):52-67.
16. Wee Y, Burns K, Bett N. 2015 Aug. Medical management of chronic stable angina. Aust Prescr. 38(4):131-6.
17. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. 2007 Apr 12. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med.; 356(15):1503-16.
18. Rayner-Hartley E, Sedlak T. 2016. Ranolazine: A Contemporary Review. J Am Heart Assoc. Mar 15; 5(3):e003196.
19. Rab T, Ratanapo S, Kern KB, Basir MB, McDaniel M, Meraj P, King SB, O'Neill W. 2018 Oct 16. Cardiac Shock Care Centers: JACC Review Topic of the Week. J Am Coll Cardiol. ;72(16):1972-1980
20. Kosaraju A, Pendela VS, Hai O. 2024 Jan. Cardiogenic Shock. [Updated 2023 Apr 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;
21. Santucci A, Cavallini C. 2018 Oct. [Which role today for intra-aortic balloon counterpulsation?]. G Ital Cardiol (Rome). ; 19(10):533-541.
22. Santucci A, Cavallini C. 2018. [Which role today for intra-aortic balloon counterpulsation?]. G Ital Cardiol (Rome). ; 19(10):533-541.
23. Ross R. Atherosclerosis — an Inflammatory Disease" New England Journal of Medicine. 1999; 340:115–26.
24. Tavafi M. 2013 Complexity of diabetic nephropathy pathogenesis and design of investigations. J Renal Inj Prev.; 2:61–5.
25. Behradmanesh S, Nasri P. 2012. Serum cholesterol and LDL-C in association with level of diastolic blood pressure in type 2 diabetic patients. J Renal Inj Prev.; 1:23–6.
26. Lu L, Liu M, Sun R, Zheng Y, Zhang P. 2015. Myocardial infarction: symptoms and treatments. Cell Biochem Biophys.; 72(3):865–867.
27. Anderson JL, Morrow DA. 2017 Acute myocardial infarction. N Engl J Med.; 376(21):2053-2064.
28. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. 2019. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 234(10):16812–16823.
29. Mehta LS, Beckie TM, DeVon HA et al. 2016. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 133(9): 916-947.
30. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022. AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 145(18):e895-e1032.
31. Ziaeian B, Fonarow GC. 2016 Jun. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. ; 13(6):368-78.
32. Malik A, Brito D, Vaqar S, Chhabra L. Congestive Heart Failure. 2023 Nov 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 28613623.